149 related articles for article (PubMed ID: 35114046)
1. Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up.
Larsen TL; Garresori H; Brekke J; Enden T; Frøen H; Jacobsen EM; Quist-Paulsen P; Porojnicu AC; Ree AH; Torfoss D; Osvik Velle E; Skuterud Wik H; Ghanima W; Sandset PM; Dahm AEA
J Thromb Haemost; 2022 May; 20(5):1166-1181. PubMed ID: 35114046
[TBL] [Abstract][Full Text] [Related]
2. Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial.
McBane RD; Loprinzi CL; Zemla T; Tafur A; Sanfilippo K; Liu JJ; Garcia DA; Heun J; Gundabolu K; Onitilo AA; Perepu U; Drescher MR; Henkin S; Houghton D; Ashrani A; Billett H; McCue SA; Lee MK; Le-Rademacher JG; Wysokinski WE;
J Thromb Haemost; 2024 Jun; 22(6):1704-1714. PubMed ID: 38537780
[TBL] [Abstract][Full Text] [Related]
3. Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism.
Hannevik TL; Brekke J; Enden T; Frøen H; Garresori H; Jacobsen EM; Paulsen PQ; Porojnicu AC; Ree AH; Torfoss D; Velle EO; Wik HS; Ghanima W; Sandset PM; Dahm AEA
Thromb Res; 2020 Dec; 196():238-244. PubMed ID: 32919178
[TBL] [Abstract][Full Text] [Related]
4. Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial.
McBane RD; Loprinzi CL; Ashrani A; Lenz CJ; Houghton D; Zemla T; Le-Rademacher JG; Wysokinski WE
Eur J Haematol; 2020 Feb; 104(2):88-96. PubMed ID: 31606897
[TBL] [Abstract][Full Text] [Related]
5. Comparison of effectiveness and safety for low versus full dose of apixaban during extended phase oral anticoagulation in patients with venous thromboembolism.
DeRemer CE; Dietrich EA; Kang HR; Huang PL; Lo-Ciganic WH; Park H
J Intern Med; 2022 Jun; 291(6):877-885. PubMed ID: 35192737
[TBL] [Abstract][Full Text] [Related]
6. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.
Weycker D; Li X; Wygant GD; Lee T; Hamilton M; Luo X; Vo L; Mardekian J; Pan X; Burns L; Atwood M; Hanau A; Cohen AT
Thromb Haemost; 2018 Nov; 118(11):1951-1961. PubMed ID: 30357780
[TBL] [Abstract][Full Text] [Related]
8. Risk Factors for Bleeding in Cancer Patients Treated with Conventional Dose Followed by Low-Dose Apixaban for Venous Thromboembolism.
Hussaini P; Larsen TL; Ghanima W; Dahm AEA
Thromb Haemost; 2024 Apr; 124(4):351-362. PubMed ID: 37816388
[TBL] [Abstract][Full Text] [Related]
9. Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study.
Mahé I; Agnelli G; Ay C; Bamias A; Becattini C; Carrier M; Chapelle C; Cohen AT; Girard P; Huisman MV; Klok FA; López-Núñez JJ; Maraveyas A; Mayeur D; Mir O; Monreal M; Righini M; Samama CM; Syrigos K; Szmit S; Torbicki A; Verhamme P; Vicaut E; Wang TF; Meyer G; Laporte S
Thromb Haemost; 2022 Apr; 122(4):646-656. PubMed ID: 34535037
[TBL] [Abstract][Full Text] [Related]
10. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
McBane RD; Wysokinski WE; Le-Rademacher JG; Zemla T; Ashrani A; Tafur A; Perepu U; Anderson D; Gundabolu K; Kuzma C; Perez Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Houghton DE; Vishnu P; Loprinzi CL
J Thromb Haemost; 2020 Feb; 18(2):411-421. PubMed ID: 31630479
[TBL] [Abstract][Full Text] [Related]
11. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis.
Cohen A; Keshishian A; Lee T; Wygant G; Rosenblatt L; Hlavacek P; Mardekian J; Wiederkehr D; Sah J; Luo X
Thromb Haemost; 2021 Mar; 121(3):383-395. PubMed ID: 33171521
[TBL] [Abstract][Full Text] [Related]
13. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
[TBL] [Abstract][Full Text] [Related]
14. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L
J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277
[TBL] [Abstract][Full Text] [Related]
15. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
16. Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity.
Crouch A; Ng TH; Kelley D; Knight T; Edwin S; ; Giuliano C
Pharmacotherapy; 2022 Feb; 42(2):119-133. PubMed ID: 34904263
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
Quon P; Le HH; Raymond V; Mtibaa M; Moshyk A
J Med Econ; 2016 Jun; 19(6):557-67. PubMed ID: 26761644
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.
Dawwas GK; Brown J; Dietrich E; Park H
Lancet Haematol; 2019 Jan; 6(1):e20-e28. PubMed ID: 30558988
[TBL] [Abstract][Full Text] [Related]
19. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467
[No Abstract] [Full Text] [Related]
20. Safety and Effectiveness of Apixaban in Japanese Patients With Venous Thromboembolism in Clinical Practice - A Post-Marketing Surveillance.
Yamada N; Mo M; Ohsawa A; Sato M; Umeyama M; Shima D; Nakamura M
Circ J; 2021 Nov; 85(12):2201-2207. PubMed ID: 33994408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
